Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.60p -0.34% 1,646.20p 1,649.20p 1,650.00p 1,660.60p 1,635.00p 1,651.80p 5,882,481 16:35:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,821.0 4,048.0 73.7 22.3 81,725

Glaxosmithkline Share Discussion Threads

Showing 19626 to 19650 of 20200 messages
Chat Pages: Latest  796  795  794  793  792  791  790  789  788  787  786  785  Older
DateSubjectAuthorDiscuss
08/5/2019
12:45
Not necessarily. Its possible that the Consumer Healthcare business, once floated, will take the burden of debt with it.
tradermichael
08/5/2019
12:10
GSK becomes more risky with the corporation split Emma is planning. The Pharma side becomes all the more risky, as does any divi payout associated with it, once the Consumer Biz is Ipo'd off and the corporate restructuring is complete.
crossing_the_rubicon
08/5/2019
10:41
GSK has IMO been a forex hedge for some time. That is fine too.
alphorn
08/5/2019
10:19
…. and yes!! GSK goes ex-div (again) next week on 16 May ….. ;0)
tradermichael
08/5/2019
09:26
Plus, with the swings in share price, much higher return if you continually buy troughs and sell peaks.
tradermichael
08/5/2019
09:25
Much higher return if you continuously re-invest the dividends.
tradermichael
08/5/2019
09:24
Reality, buy shares on 1 Jan 1995 at 618p Hold and collect dividends, total dividends: 1430 Profit (by today) is 1430-618 = 800p, with your shares owing you 0p
tradermichael
08/5/2019
09:19
That's why I say this like owning a corporate bond, but with more risk, yes income but no shareprice growth.
montyhedge
08/5/2019
09:17
Yes but no growth in 22 years.
montyhedge
08/5/2019
09:08
My figures are: Total dividends paid out since 2000: 1234p since Mar 1998: 1342p Since Sep 1995: 1430p
tradermichael
08/5/2019
08:41
OK, and the total dividends paid out in that period, please?
tradermichael
07/5/2019
22:11
Let's assess the facts. 2002 GSK £16.34 2019 GSK £15.17 H £20.94 Jan 1999 Range bound 2002 onwards. Monty correct - no growth since 2002. 22 years ago is 1997. Price in 1997 was: £14.05 Dec 1997. A high? So essentially range bound since 1997 with a two year peak 2000-2001
gordogecks
07/5/2019
13:43
They were over £20; max around £23???
alphorn
07/5/2019
13:38
Below the price their 22 years ago when they were 1550p. No growth whatsoever in GSK.
montyhedge
03/5/2019
20:20
BREAKING: GlaxoSmithKline Hit With $89.7M Verdict For Inhaler IP Law360 (May 3, 2019, 1:46 PM EDT) -- A federal jury in Delaware found Friday that GlaxoSmithKline LLC and Glaxo Group Ltd. owe $89.7 million to U.K.-based Vectura Ltd. for infringing a single claim of a patent covering features...
cityfarmer
03/5/2019
09:33
Coupled with the above post - where is the cash geographically versus the point of payment of dividends? (Relevant to many global companies).
alphorn
03/5/2019
09:30
Morning everyone , ticking along nicely. Glaxo struggles with cash conversion GlaxoSmithKline (GSK) has delivered profits ahead of expectations but it is still struggling to turn them into cash, says Hargreaves Lansdown. First quarter product sales rose 5% to £7.7 billion boosted by strong results in pharmaceuticals and vaccines, as well as success with a new respiratory treatment. ‘However, GSK has again struggled to turn profits into cash, an area where it’s a serial offender,’ said analyst Nicholas Hyett. ‘Cash conversion has deteriorated significantly, partly down to timing, but also because headline profitability is being flattered by revaluations that don’t turn up in the all-important cashflow statement.’ Hyett said investors should give the pharma giant ‘the benefit of the doubt, at least for now’, as product launches have performed well and the labs are busy. HTTPS://citywire.co.uk/funds-insider/news/the-expert-view-glaxosmithkline-domino-s-pizza-and-jupiter/a1225494?section=funds-insider&_ga=2.189410472.206969991.1556872124-191019866.1556872124#i=2
philanderer
03/5/2019
08:32
The merger and subsequent divestment of the Consumer Healthcare business will herald a new era for the company …. ;0)
tradermichael
03/5/2019
08:28
Price below what it was 22 years ago, it's a income stock and not a growth share, it's like having a corporate bond but with more risk. Wonder if it will be this price in 22 years time.
montyhedge
02/5/2019
15:55
So now it's all up to the rats,the ball is in their court.
abdullla
02/5/2019
14:30
Yeah thats exactly what we are wishing for, a plague, that only gsk have the cure for and we all cash out with huge profits at 50 quid a share bwahaha
porsche1945
02/5/2019
13:30
All agreed,just testing.
abdullla
02/5/2019
11:57
Of course without shareholders no life saving drugs, no pharma companies.
montyhedge
02/5/2019
11:55
GSK's 150 year history has brought improved health to and saved the lives of millions of people worldwide, enabling them to "Do more, feel better live longer". As shareholders, supporting this quest, its never unreasonable to expect an investment return.
tradermichael
02/5/2019
11:13
No investor has to wish for nasty illnesses.A rising global population and increased longevity pretty much assures rising demand for medication.
steeplejack
Chat Pages: Latest  796  795  794  793  792  791  790  789  788  787  786  785  Older
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191020 12:22:10